IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i17p10879-d903323.html
   My bibliography  Save this article

Smoking Cessation Programs Are Less Effective in Smokers with Low Socioeconomic Status Even When Financial Incentives for Quitting Smoking Are Offered—A Community-Randomized Smoking Cessation Trial in Denmark

Author

Listed:
  • Charlotta Pisinger

    (Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
    Department of Public Health, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
    Danish Heart Foundation, 1120 Copenhagen, Denmark)

  • Cecilie Goltermann Toxværd

    (Department of Public Health, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark)

  • Mette Rasmussen

    (Clinical Health Promotion Centre, WHO-CC, The Parker Institute, Bispebjerg & Frederiksberg Hospital, 2000 Frederiksberg, Denmark
    Clinical Health Promotion Centre, WHO-CC, Department of Health Sciences, Lund University, 223 62 Lund, Sweden)

Abstract

Financial incentives offered to those who quit smoking have been found effective, also in persons with low socioeconomic status (SES), but no previous study has investigated who benefits most: smokers with low or high SES. In this community-randomized trial (“Richer without smoking”), three Danish municipalities were randomized to reward persons who were abstinent when attending the municipal smoking cessation program (FIMs) and three municipalities were randomized to spend the same amount on smoking cessation campaigns recruiting smokers to the smoking cessation program (CAMs). The municipalities each received approximately USD 16,000. An intention-to-treat approach was used in analyses. In regression analyses adjusted for individual- and municipal-level differences, we found that smokers with high SES living in FIMs had significantly higher proportion of validated long-term successful quitters (OR (95% CI): 2.59 (1.6–4.2)) than high-SES smokers living in CAM. Smokers with low SES, however, did not experience the same benefit of financial incentives as smokers with high SES. Neither the FIMs nor the CAMs succeeded in attracting more smokers with low SES during the intervention year 2018 than the year before. Our study showed that smokers with low SES did not experience the same benefit of financial incentives as smokers with high SES.

Suggested Citation

  • Charlotta Pisinger & Cecilie Goltermann Toxværd & Mette Rasmussen, 2022. "Smoking Cessation Programs Are Less Effective in Smokers with Low Socioeconomic Status Even When Financial Incentives for Quitting Smoking Are Offered—A Community-Randomized Smoking Cessation Trial in," IJERPH, MDPI, vol. 19(17), pages 1-15, August.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10879-:d:903323
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/17/10879/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/17/10879/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Kendzor, D.E. & Businelle, M.S. & Poonawalla, I.B. & Cuate, E.L. & Kesh, A. & Rios, D.M. & Ma, P. & Balis, D.S., 2015. "Financial incentives for abstinence among socioeconomically disadvantaged individuals in smoking cessation treatment," American Journal of Public Health, American Public Health Association, vol. 105(6), pages 1198-1205.
    2. Ryan J. Courtney & Sundresan Naicker & Anthony Shakeshaft & Philip Clare & Kristy A. Martire & Richard P. Mattick, 2015. "Smoking Cessation among Low-Socioeconomic Status and Disadvantaged Population Groups: A Systematic Review of Research Output," IJERPH, MDPI, vol. 12(6), pages 1-20, June.
    3. Marek Milcarz & Kinga Polanska & Leokadia Bak-Romaniszyn & Dorota Kaleta, 2018. "Tobacco Health Risk Awareness among Socially Disadvantaged People—A Crucial Tool for Smoking Cessation," IJERPH, MDPI, vol. 15(10), pages 1-12, October.
    4. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    2. Ryuichi Ohta & Yoshinori Ryu & Daisuke Kataoka & Chiaki Sano, 2021. "Effectiveness and Challenges in Local Self-Governance: Multifunctional Autonomy in Japan," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    3. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    4. Scott Metcalfe & Rachel Grocott, 2010. "Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966”—New Zealand in Fact Has No Cost-Effectiveness Threshold," IJERPH, MDPI, vol. 7(4), pages 1-4, April.
    5. Marieke Krol & Jocé Papenburg & Siok Swan Tan & Werner Brouwer & Leona Hakkaart, 2016. "A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(4), pages 391-402, May.
    6. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    7. Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
    8. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    9. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    10. Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
    11. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    12. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    13. Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma, 2021. "Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 75-88, February.
    14. Finkelstein, Eric A. & Bilger, Marcel & Baid, Drishti, 2019. "Effectiveness and cost-effectiveness of incentives as a tool for prevention of non-communicable diseases: A systematic review," Social Science & Medicine, Elsevier, vol. 232(C), pages 340-350.
    15. Stefano Capri & Rosella Levaggi, 2011. "Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs," DEP - series of economic working papers 2/2011, University of Genoa, Research Doctorate in Public Economics.
    16. Nadine Schur & Salvatore Brugaletta & Angel Cequier & Andrés Iñiguez & Antonio Serra & Pilar Jiménez-Quevedo & Vicente Mainar & Gianluca Campo & Maurizio Tespili & Peter den Heijer & Armando Bethencou, 2018. "Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial," PLOS ONE, Public Library of Science, vol. 13(8), pages 1-16, August.
    17. Anne Girault & Chloe Gerves-Pinquie & Serena Phillips & Sarah Raskin & Mandi Pratt-Chapman, 2018. "Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review," Post-Print hal-01973691, HAL.
    18. Chloé Gervès-Pinquié & Anne Girault & Serena Phillips & Sarah Raskin & Mandi Pratt-Chapman, 2018. "Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    19. Benjamin Cadier & Isabelle Durand-Zaleski & Daniel Thomas & Karine Chevreul, 2016. "Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
    20. Matthew Taing & Bryce Kyburz & Isabel Martinez Leal & Kathy Le & Tzu-An Chen & Virmarie Correa-Fernandez & Teresa Williams & Daniel P. O’Connor & Ezemenari M. Obasi & Kathleen Casey & Litty Koshy & Lo, 2020. "Clinician Training in the Adaptation of a Comprehensive Tobacco-Free Workplace Program in Agencies Serving the Homeless and Vulnerably Housed," IJERPH, MDPI, vol. 17(17), pages 1-15, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10879-:d:903323. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.